Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Petros Pharmaceuticals Inc
(NQ:
PTPI
)
0.3150
-0.0199 (-5.94%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Petros Pharmaceuticals Inc
< Previous
1
2
Next >
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
September 11, 2024
Via
ACCESSWIRE
Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
Via
ACCESSWIRE
Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
July 29, 2024
Via
ACCESSWIRE
Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
July 16, 2024
Via
ACCESSWIRE
Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch
May 29, 2024
Via
ACCESSWIRE
Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA
May 21, 2024
Via
ACCESSWIRE
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
April 16, 2024
Via
ACCESSWIRE
Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider
February 14, 2024
Via
ACCESSWIRE
Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch
January 24, 2024
Via
ACCESSWIRE
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
May 14, 2024
Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activity
From
23andMe, Inc.
Via
GlobeNewswire
Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe
May 14, 2024
Via
ACCESSWIRE
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health
April 23, 2024
Via
ACCESSWIRE
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
April 02, 2024
Via
ACCESSWIRE
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor’s (rosuvastatin) OTC Switch Technology Provider
December 12, 2023
Via
ACCESSWIRE
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology Provider
December 05, 2023
Via
ACCESSWIRE
Following Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA
October 19, 2023
Via
ACCESSWIRE
Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider
March 19, 2024
Via
ACCESSWIRE
BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc
March 11, 2024
NEW YORK, NY / NewsDirect / March 11th, 2024 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing...
Via
TheNewswire.com
Exposures
Product Safety
Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch
January 17, 2024
Via
ACCESSWIRE
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status
December 12, 2023
Via
ACCESSWIRE
Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)
October 30, 2023
Via
ACCESSWIRE
Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA Label
October 04, 2023
Via
ACCESSWIRE
Petros Pharmaceuticals Provides Letter to Shareholders
September 11, 2023
Via
ACCESSWIRE
Petros Pharmaceuticals Announces Capital Raise of $15 Million
July 13, 2023
Via
ACCESSWIRE
Petros Pharmaceuticals Announces Reverse Stock Split
November 30, 2022
Via
ACCESSWIRE
Petros Pharmaceuticals to Present at the LD Micro Main Event XVI
September 28, 2023
Via
ACCESSWIRE
Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
Via
ACCESSWIRE
Petros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Update
November 15, 2022
Via
ACCESSWIRE
New FDA-Approved Labeling for Petros Pharmaceuticals’ STENDRA (avanafil) Now Includes Efficacy Data Regarding Use in Men Who Have Undergone Radical Prostatectomy
October 25, 2022
Via
ACCESSWIRE
Petros Pharmaceuticals to Participate in Two October 2022 Conferences
October 21, 2022
Via
ACCESSWIRE
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.